Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis

The use of bispecific antibodies (BsAbs) in the treatment of relapsed/refractory multiple myeloma (MM) is showing early promising overall response rates in heavily pretreated patients. Infectious complications related to the use of BsAbs are not well described. We conducted a pooled analysis that in...

Descripción completa

Detalles Bibliográficos
Autores principales: Mazahreh, Farah, Mazahreh, Liyan, Schinke, Carolina, Thanendrarajan, Sharmilan, Zangari, Maurizio, Shaughnessy, John D., Zhan, Fenghuang, van Rhee, Frits, Al Hadidi, Samer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331406/
https://www.ncbi.nlm.nih.gov/pubmed/36857755
http://dx.doi.org/10.1182/bloodadvances.2022009435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331406/
https://www.ncbi.nlm.nih.gov/pubmed/36857755
http://dx.doi.org/10.1182/bloodadvances.2022009435

Ejemplares similares